Overview

ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics and safety of ASP8825 in patients with impaired renal function and haemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Gabapentin